Search Results

1 - 6 of 6 items :

  • Rheumatology x
Clear All
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease

of steatohepatitis in mice. J Inflamm (Lond). 2011; 8:8. 9. PARK SH, KIM BI, KIM SH, KIM HJ, PARK DI, CHO YK, SUNG IK, SOHN CI, KIM H, KEUM DK, KIM HD, PARK JH, KANG JH, JEON WK. Body fat distribution and insulin resistance: beyond obesity in nonalcoholic fatty liver disease among overweight men. J Am Coll Nutr 2007; 26:321-326. 10. PARK BJ, KIM YJ, KIM DH, KIM W, JUNG YJ, YOON JH, KIM CY, CHO YM, KIM SH, LEE KB, JANG JJ, LEE HS. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol

Open access
Non-alcoholic fatty pancreas disease – practices for clinicians

REFERENCES 1. ALEMPIJEVIC T., DRAGASEVIC S., ZEC S., POPOVIC D., MILOSAVLJEVIC T. Non-alcoholic fatty pancreas disease. Postgrad Med J 2017; 93 (1098):226-230. 2. SMITS M.M., VAN GEENEN E.J.M. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 2011; 8 (3): 169-177. 3. ROMANA B.S., CHELA H., DAILEY F.E., NASSIR F., TAHAN V. Non-alcoholic fatty pancreas disease (NAFPD). A silent spectator or the fifth component of metabolic syndrome? A literature review. Endocrine Metab Immune Disord – Drug Targets 2018; 18

Open access
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes

X., Sun A., et al. Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells . Biochem Biophys Res Commun. 2018; 499 (2):267-72. 7. INOUE T., INOGUCHI T., SONODA N., HENDARTO H., MAKIMURA H., SASAKI S., et al. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats . Atherosclerosis 2015; 240 (1):250-9. 8. AGRAWAL R., ZHUANG Y., CUMMINGS BP., STANHOPE KL., GRAHAM JL., HAVEL PJ., GOMEZ-PINILLA F. Deterioration of

Open access
Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth

., DESCHENES M. Antioxidant therapy in nonalcoholic steatohepatitis . Hepat Res Treat. 2012; 22 : 947575. 7. VIGANÒ M., VERGANI A., TROMBINI P., POZZI M., PALEARI F., PIPERNO A. Insulin resistance influences iron metabolism and hepatic steatosis in type II diabetes. Gastroenterology. 2000; 118 (5):986-7. 8. COHEN B., NOVICK D., RUBINSTEIN M. Modulation of insulin activities by leptin. Science. 1996; 274 (5290):1185. 9. PAPPO I., BERCOVIER H., BERRY E., GALLILLY R., FEIGIN E., FREUND HR. Antitumor necrosis factor antibodies reduce hepatic steatosis

Open access
Liver Fibrosis: Causes and Methods of Assessment, A Review

Shear Imaging with ARFI and FibroScan® . Journal of Hepatology 2014; 61(3) : 550-557. 60. CROSS TJS, CALVARUSO V, MAIMONE S, CAREY I, CHANG TP, PLEGUEZUELO M, et al . Prospective comparison of FibroScan®, king’s score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection . J Viral Hepat 2010; 17(8) : 546-554. 61. MACALUSO FS, MAIDA M, CAMMÀ C, CABIBBO G, CABIBI D, ALDUINO R, DI MARCO V, et al . Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic

Open access
Liver stiffness in chronic hepatitis C virus infection

: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis C . J Viral Hepat 2018; 25 :335-43. 16. CONTI F., SERRA C., VUKOTIC R., FIORINI E., FELICANI C., MAZZOTTA E., et al. Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C . Liver Int 2017; 37 :187-95. 17. BOTA S, SPOREA I, PECK-RADOSAVLJEVIC M, SIRLI R, TANAKA H, IIJIMA H, et al. The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force

Open access